APTOF · As filed with the SEC
Aptose Biosciences cash flow statement, by fiscal year
The statement as Aptose Biosciences presents it in its 10-Q and 10-K: its own lines, labels and order. Tables over time lines up standardized figures across every filing.
Consolidated Statements of Cash Flows · USD
| USD | FY2025 Year ended Dec 31, 2025 | FY2024 Year ended Dec 31, 2024 | FY2023 Year ended Dec 31, 2023 | FY2022 Year ended Dec 31, 2022 |
|---|---|---|---|---|
| Cash flows from operating activities: | ||||
| Net loss | (25,468,000) | (25,430,000) | (51,207,000) | (41,823,000) |
| Adjustments to reconcile net loss to cash used in operating activities: | ||||
| Stock-based compensation | 477,000 | 1,060,000 | 3,653,000 | 5,207,000 |
| Shares issued to Hanmi Pharmaceutical as license fees | — | — | — | 0 |
| Depreciation and amortization | — | — | 88,000 | 120,000 |
| Change in fair value of warrants | 0 | (686,000) | — | — |
| Depreciation of property and equipment | 22,000 | 32,000 | — | — |
| Loss on disposal of property and equipment | 0 | 76,000 | 0 | 16,000 |
| Amortization of right-of-use assets | — | 372,000 | 378,000 | 408,000 |
| Interest on lease liabilities | — | 64,000 | 93,000 | 35,000 |
| Unrealized foreign exchange gain/(loss) | — | — | 0 | 4,000 |
| Accrued interest on investments | — | — | 0 | (60,000) |
| Interest on loan payable to related party | — | 18,000 | — | — |
| Noncash operating lease expense | 396,000 | — | — | — |
| Interest on lease liabilities | 34,000 | — | — | — |
| Interest on loan payable to related party | 843,000 | — | — | — |
| Change in operating assets and liabilities: | ||||
| Prepaid expenses | 44,000 | (211,000) | 261,000 | 173,000 |
| Operating lease payments | — | (458,000) | (405,000) | (546,000) |
| Other assets | (2,958,000) | 30,000 | (343,000) | (124,000) |
| Accounts payable | — | — | — | 4,627,000 |
| Accounts payable | — | 0 | — | — |
| Change in operating lease liability | (462,000) | — | — | — |
| Accounts payable | 1,653,000 | — | — | — |
| Accounts payable, related party | 0 | (2,554,000) | (430,000) | — |
| Accounts payable | — | (2,234,000) | 150,000 | — |
| Accrued liabilities, related party | — | 0 | (572,000) | — |
| Accrued liabilities | 3,429,000 | (6,056,000) | 3,744,000 | (359,000) |
| Cash used in operating activities | (21,990,000) | (35,977,000) | (44,590,000) | (32,322,000) |
| Cash flows from investing activities: | ||||
| (Acquisition) maturity of investments, net | — | — | 9,989,000 | 30,090,000 |
| Maturity of investments, net | — | 0 | — | — |
| Proceeds from disposal of property and equipment | 0 | 23,000 | — | — |
| Purchase of property and equipment | 0 | (5,000) | (29,000) | (24,000) |
| Cash provided by investing activities | 0 | 18,000 | 9,960,000 | 30,066,000 |
| Cash flows from financing activities: | ||||
| Proceeds from loan payable with related parties | 18,650,000 | 10,000,000 | — | — |
| November 2024 Public Offering | — | 6,920,000 | — | — |
| January 2024 Public Offering | — | 8,127,000 | — | — |
| Hanmi Private Placement | — | 3,701,000 | — | — |
| Repayment of loan with related party | (100,000) | — | — | — |
| November 2024 Public Offering | 0 | — | — | — |
| January 2024 Public Offering | 0 | — | — | — |
| Hanmi Private Placement | 0 | — | — | — |
| Hanmi | — | — | 2,989,000 | — |
| The 2020 ATM Offering | — | — | 0 | 50,000 |
| June 2024 Registered Direct Offering | — | 4,024,000 | — | — |
| 2023 Committed Equity Facility | — | 635,000 | — | — |
| The 2022 ATM Offering | — | (21,000) | 1,809,000 | 51,000 |
| Issuance of common shares pursuant to exercise of stock options | — | — | 0 | 15,000 |
| ESPP | — | 26,000 | 29,000 | — |
| 2023 Committed Equity Facility | — | — | 2,083,000 | — |
| June 2024 Pre-funded Warrants | — | 2,000 | — | — |
| June 2024 Registered Direct Offering | 0 | — | — | — |
| 2023 Committed Equity Facility | 0 | — | — | — |
| The 2022 ATM Offering | 0 | — | — | — |
| The 2025 ATM Offering | 828,000 | — | — | — |
| ESPP | 1,000 | — | — | — |
| June 2024 Pre-funded Warrants | 0 | — | — | — |
| Cash provided by financing activities | 19,379,000 | 33,414,000 | 6,910,000 | 116,000 |
| Effect of exchange rate fluctuations on cash and cash equivalents | — | 0 | 2,000 | (4,000) |
| Decrease in cash, cash equivalents, restricted cash and restricted cash equivalent | (2,611,000) | (2,545,000) | (27,718,000) | (2,144,000) |
| Cash, cash equivalents, restricted cash and restricted cash equivalents, beginning of year | 6,707,000 | 9,252,000 | 36,970,000 | 39,114,000 |
| Cash, cash equivalents, restricted cash and restricted cash equivalents, end of the year | 4,096,000 | 6,707,000 | 9,252,000 | 36,970,000 |
As filed on EDGAR · Not affiliated with the U.S. SEC · Not investment advice. Each column links to its filing.